title: Effect of adriamycin, 5-fluorouracil and mitomycin-C combination chemotherapy in advanced colorectal cancer.
abstract: One hundred and seventy-four patients with advanced colorectal cancer were treated with 5-fluorouracil (5-FU), mitomycin-C (MIT-C) and Adriamycin (ADR) (FAM). The total response rate was 26.4%. A higher response rate (37%) was observed in patients with liver metastases only, compared to other sites of metastases (p < 0.02). Complete remission were achieved only in patients with liver metastases (15%). Male patients with liver metastases had a higher response rate than females (p < 0.03). Twenty-five patients previously treated unsuccessfully with 5-FU and MIT-C showed a response rate of 28% when ADR was added to the regimen. The patients' median survival was 11 months (range: from 3 to > or = 60 months). The median survival of patients with liver metastases was 11 months and that of responders (20 months) was significantly longer than that of nonresponders (7 months; p < 0.0001). These results suggest that the FAM combination might be considered an eligible chemotherapy schedule for patients with liver metastatic disease from colorectal cancer.
authors.affiliation: Second University Department of Medicine, Hippokration Hospital, Athens, Greece.
authors.forename: G P
authors.initials: GP
authors.lastname: Stathopoulos
authors.forename: G S
authors.initials: GS
authors.lastname: Stergiou
authors.forename: B
authors.initials: B
authors.lastname: Golematis
authors.forename: N
authors.initials: N
authors.lastname: Thalassinos
authors.forename: M
authors.initials: M
authors.lastname: Fillipakis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D012737:Sex Factors; D016019:Survival Analysis
chemical_list: D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil